stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Bioprojet Pharma

France ยท Privately owned

Bioprojet develops first-in-class prescription medicines for narcolepsy, excessive sleepiness, and rare diseases, which are sold through distributors and licensing partners.

Bioprojet is a small French drugmaker that focuses on a handful of brain and sleep disorders where patients have few good options. Its best-known medicine is pitolisant, sold under the brand name Wakix, which treats narcolepsy โ€” a condition where people can fall asleep suddenly and uncontrollably during the day. Wakix is a "first-in-class" drug, meaning it works in a way no other approved medicine did before, and that originality is the core of Bioprojet's story.

The company doesn't market its drugs around the world itself. Instead, it partners with larger firms that handle the selling, and it collects money through licensing deals and distributor arrangements. In the United States, Wakix is commercialized by Harmony Biosciences, a publicly traded company that licenses the drug and has built much of its business around it. That kind of partnership lets a tiny company like Bioprojet reach patients at scale without building a global sales force of its own. Bioprojet is privately held and based in Paris. It is a genuine research shop: it discovers and develops its own molecules rather than copying drugs that already exist. Beyond narcolepsy, it works on other rare diseases, which are often overlooked by big pharmaceutical companies because the patient pools are small. For Bioprojet, that neglect is the opportunity โ€” small markets with serious unmet needs and little competition.


The business is quietly important out of proportion to its size. A single successful first-in-class drug can generate steady royalty and licensing income for years, and Wakix has become a meaningful treatment for narcolepsy patients in the US and Europe. The trade-off is dependence: Bioprojet's fortunes lean heavily on a few products and on the partners who sell them, so a setback in one drug or one deal matters a lot more here than it would at a giant drugmaker.

Saved answer ยท last researched 16 Nov 2026